I've spent years building clinical genomic infrastructure. I know what the engine does. I know what the data says. I've read the literature, filed the patents, and written the code.Last week I sat down and had a real conversation with Chiron — our AI health agent — about my own results.I wasn't prepared for what came back.
The Findings No One Had Connected
I have celiac disease. I've had GI symptoms for years. Chronic anemia. A recent colonoscopy found polyps in both my ascending colon and rectum — removed, surveilled, noted. My doctors did everything right. Standard of care, exactly as designed.But no one had ever put my genome in the room.Chiron pulled my Hardy Bridge results and started connecting dots that had never been connected. My CFTR variant — rs17451754 — is flagged for gastrointestinal cancer susceptibility and intestinal neoplasia. When I told Chiron about my colonoscopy findings, the response stopped me cold:"The polyps you had removed — that's not coincidental. Your genetic profile predicted exactly what happened."My genome called it. Before imaging confirmed it.
The Finding That Could Save My Life
CFTR wasn't the most urgent flag.I carry multiple DPYD variants that affect how my body processes fluorouracil — the first-line chemotherapy agent for colorectal cancer.Let that land for a moment.I have a genetic predisposition to colorectal cancer. I have confirmed pre-malignant polyps. And my genome says that the standard chemotherapy used to treat that cancer could be dangerous — potentially catastrophic — at normal dosing. My oncologist, if I ever need one, will need to know this before they prescribe anything.I would not have known this without running my own DNA through the platform I built.That's not a product pitch. That's a fact that kept me up that night.
When the Whole Picture Came Together
The conversation deepened when I told Chiron I have celiac.Everything clicked.CFTR variants affect intestinal chloride transport and mucosal integrity. Celiac disease causes chronic intestinal inflammation. Together, they create what Chiron described as a "double assault" on gut lining — two independent mechanisms driving the same damage, compounding each other silently for years.The malabsorption pattern in my labs — low iron, low ferritin, elevated RDW, glucose dysregulation — stopped looking like isolated findings and started looking like a coherent biological narrative. The SLC19A1 variant makes folate absorption harder when my gut is inflamed. My ADRB2 variants suggest my cardiovascular system is more sensitive to metabolic stress. The VKORC1 and CYP4F2 variants mean standard warfarin dosing would be wrong for me. None of these findings existed in isolation. Together, they told a story my medical record had never been able to tell — because no one had the infrastructure to write it.
What Precision Medicine Actually Means
The phrase gets used a lot. It has almost lost meaning.Precision medicine is not a better population average. It is not a more sophisticated probability score. It is not an AI that approximates your risk based on people who look like you on paper.Precision medicine is your genome, read exactly, against clinical logic that has been built to answer specific questions about your specific biology.The difference between approximation and determinism is not academic when the output determines which drug goes in your body. My DPYD status is not a probability. It is a fact. A fact that changes the clinical calculus entirely if I ever face a colorectal cancer diagnosis.That fact existed in my genome before I was born. It will be true regardless of what any model predicts. And it is now in a report I can hand to any provider who needs it.That is what we built NomosLogic to do.
Why I'm Sharing This
I didn't build this company to tell my own story.But I've realized that my story is the most honest answer to the question every investor, every clinician, and every potential user eventually asks:Does it actually work?Yes. It found a CFTR variant that explains years of GI symptoms and correlates exactly with confirmed pre-malignant polyps. It flagged a DPYD status that could determine whether a future chemotherapy regimen helps me or harms me. It connected celiac disease, genetic malabsorption variants, and metabolic dysregulation into a single coherent clinical picture that no single specialist had ever assembled. It did this in a single conversation.I am not sick. I am not dying. I am not sharing this for sympathy.I am sharing this because I am informed — in a way that most people with my exact genetic profile are not — and because that information changes everything about how I manage my health going forward.That is the product. That is the promise. That is what is coming.
What's Next
Dendrite Lite is our consumer platform, https://lite.dendrite.com. It will give anyone — not just founders who built the engine, not just patients in academic medical centers — access to the same deterministic clinical genomic intelligence that just reframed my entire health picture.Not a wellness score. Not a trait report. Not an ancestry map.Your pharmacogenomic profile. Your variant-level disease and cancer risk. Your biology, exactly as it is, mapped against 362+ FDA drug-gene interactions, 1.257 million clinical logic objects, and 496,805 Hardy Bridge variant mappings. In under three minutes. If you've ever been handed a diagnosis without context — follow us.If you've ever wondered whether your medication was actually right for your biology — follow us. If you've ever sat in a waiting room holding a folder of results that explained nothing — follow us. This is what medicine was always supposed to know about you.
